Lymphocyte Predominant Hodgkin Lymphoma

Brandon McMahon; Jonathan W. Friedberg; Ralph M. Meyer

doi:10.1002/9781444300857.ch47

Lymphocyte Predominant Hodgkin Lymphoma

Brandon McMahon^*, Jonathan W. Friedberg, Ralph M. Meyer

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Original language	English (US)
Title of host publication	Evidence-Based Hematology
Publisher	John Wiley and Sons
Pages	372-377
Number of pages	6
ISBN (Print)	9781405157476
DOIs	https://doi.org/10.1002/9781444300857.ch47
State	Published - Feb 4 2009

Keywords

De novo LPHL and classical Hodgkin lymphoma treatment
Detection and treatment of LPHL progression or relapse
LPHL - distinct clinical/pathologic entity from classical HL
Literature-search strategy and inclusions
Lymphocyte predominant Hodgkin lymphoma (LPHL)
Rituximab - active agent in LPHL
Rituximab - included as "standard" therapeutic modality for LPHL

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/9781444300857.ch47

Cite this

@inbook{bcaf1fd24bd243a7884510cc6c9163a7,

title = "Lymphocyte Predominant Hodgkin Lymphoma",

keywords = "De novo LPHL and classical Hodgkin lymphoma treatment, Detection and treatment of LPHL progression or relapse, LPHL - distinct clinical/pathologic entity from classical HL, Literature-search strategy and inclusions, Lymphocyte predominant Hodgkin lymphoma (LPHL), Rituximab - active agent in LPHL, Rituximab - included as {"}standard{"} therapeutic modality for LPHL",

author = "Brandon McMahon and Friedberg, {Jonathan W.} and Meyer, {Ralph M.}",

year = "2009",

month = feb,

day = "4",

doi = "10.1002/9781444300857.ch47",

language = "English (US)",

isbn = "9781405157476",

pages = "372--377",

booktitle = "Evidence-Based Hematology",

publisher = "John Wiley and Sons",

}

TY - CHAP

T1 - Lymphocyte Predominant Hodgkin Lymphoma

AU - McMahon, Brandon

AU - Friedberg, Jonathan W.

AU - Meyer, Ralph M.

PY - 2009/2/4

Y1 - 2009/2/4

KW - De novo LPHL and classical Hodgkin lymphoma treatment

KW - Detection and treatment of LPHL progression or relapse

KW - LPHL - distinct clinical/pathologic entity from classical HL

KW - Literature-search strategy and inclusions

KW - Lymphocyte predominant Hodgkin lymphoma (LPHL)

KW - Rituximab - active agent in LPHL

KW - Rituximab - included as "standard" therapeutic modality for LPHL

UR - http://www.scopus.com/inward/record.url?scp=84891024752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891024752&partnerID=8YFLogxK

U2 - 10.1002/9781444300857.ch47

DO - 10.1002/9781444300857.ch47

M3 - Chapter

AN - SCOPUS:84891024752

SN - 9781405157476

SP - 372

EP - 377

BT - Evidence-Based Hematology

PB - John Wiley and Sons

ER -

Lymphocyte Predominant Hodgkin Lymphoma

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this